Skip to main content
IP Group PLC logo

IP Group PLC — Investor Relations & Filings

Ticker · IPO ISIN · GB00B128J450 LEI · 213800HG22UM138WFG43 IL Financial and insurance activities
Open in API
Filings indexed 1,208 across all filing types
Latest filing 2017-08-31 Regulatory Filings
Country GB United Kingdom
Listing IL IPO

About IP Group PLC

https://www.ipgroupplc.com/

IP Group PLC is an intellectual property commercialization firm that specializes in creating, building, and supporting early-stage, science-based businesses. The company provides capital, expertise, and strategic guidance to innovators, helping to transform groundbreaking research into tangible impact. Its investment portfolio is focused on three core sectors: life sciences, aimed at curing and preventing disease; deeptech, focused on developing disruptive technologies for digital resilience and new capabilities; and cleantech, which supports scalable solutions to address climate change. By partnering with scientists and entrepreneurs, IP Group works to develop defensible innovations with the potential to address significant global challenges, aiming to deliver both strong financial returns and positive societal impact.

Recent filings

Filing Released Lang Actions
Total Voting Rights
Regulatory Filings Classification · 98% confidence The document is identified by the 'RNS Number' header, indicating it is a regulatory announcement from the London Stock Exchange. The content explicitly states the 'total number of voting rights' and the 'issued share capital' as of the month-end date (31 August 2017). This type of disclosure, relating to the total number of shares and voting rights, is a mandatory periodic filing under Disclosure and Transparency Rules. While it relates to capital structure, it is not a formal share issue/change (SHA) or a transaction in own shares (POS). It is a routine regulatory disclosure. Since it is a specific regulatory announcement that doesn't fit the other specialized categories (like DVA for voting *results* or CAP for fundraising), it falls under the general 'Regulatory Filings' category (RNS) as a fallback for routine compliance disclosures, although it is very close to 'Share Issue/Capital Change' (SHA) in subject matter. Given the context of RNS and routine disclosure, RNS is the most appropriate general classification.
2017-08-31 English
Director/PDMR Shareholding
Remuneration Information Classification · 99% confidence The document is an official announcement released via RNS (RNS Number : 3646P) on August 30, 2017. The content details the conditional award of ordinary shares under the Long-Term Incentive Plan (LTIP) to executive directors and Persons Discharging Managerial Responsibilities (PDMRs). This type of disclosure, specifically reporting transactions by directors and PDMRs regarding company shares (even if they are conditional awards/options), falls under insider trading or director dealing notifications, which are often mandated by regulations like MAR (Market Abuse Regulation, explicitly mentioned). Among the provided codes, 'Director's Dealing (Code: DIRS)' is the most appropriate classification for reporting personal share transactions by directors and executives, even when structured as an LTIP award notification. It is not a general earnings release (ER), a full annual report (10-K), or a general regulatory filing (RNS) because it fits the specific DIRS category.
2017-08-30 English
Update on Offer for Touchstone Innovations plc
M&A Activity Classification · 100% confidence The document is an RNS (Regulatory News Service) announcement from IP Group PLC dated August 30, 2017, detailing an update on a takeover offer for Touchstone Innovations plc. It specifically reports on the level of acceptances and statements of support exceeding 90%, referencing the Offer Document, the Takeover Panel, and the CMA review. The presence of the RNS Number (3644P) and the nature of the content—a formal update on a corporate action (takeover/merger) that is not the final financial report itself—strongly indicates a regulatory announcement. Since it deals with a takeover/merger proposal, the most specific category is M&A Activity (TAR). However, because this document is explicitly formatted as an RNS release and provides an update on the status of a previously announced offer, it fits the general regulatory announcement category. Given the strong focus on the takeover bid, TAR is highly relevant, but RNS is the general regulatory filing code. Since the content is entirely about a takeover bid, TAR (M&A Activity) is the most precise fit for the subject matter, even though it is delivered via RNS. The document is not a short announcement of a report publication (RPA), but a substantive update on a transaction. I will classify it as TAR based on the subject matter (Takeover/Merger Activity).
2017-08-30 English
Holding(s) in Company
Major Shareholding Notification Classification · 98% confidence The document is explicitly labeled as an 'RNS Number' notification and uses the 'TR-1: Standard form for notification of major holdings'. This form is used to report changes in significant share ownership thresholds. The definition for 'Major Shareholding Notification' (Code: MRQ) fits this content perfectly, as it covers 'Notification of changes in significant share ownership levels (crossing thresholds)'. Although it is an RNS filing, MRQ is the more specific category for this type of regulatory disclosure.
2017-08-30 English
Istesso announces positive outcome from P1 study
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and is dated August 30, 2017. It announces positive data from a Phase 1 study for a drug candidate (MBS2320) developed by a subsidiary (Istesso), which is owned by IP Group plc. The content is a press release detailing clinical trial progress, safety, and future expectations. This type of announcement, which is not a full financial report (10-K, IR), a formal dividend notice (DIV), or a proxy statement (DEF 14A), but rather a general corporate update distributed via a regulatory news service (RNS), fits best under the general 'Regulatory Filings' category, as it is a standard market disclosure. Although it contains clinical data, it is not a formal Audit Report (AR) or a comprehensive Interim Report (IR). Since it is distributed via RNS and serves as a general corporate update, RNS is the most appropriate classification.
2017-08-30 English
Portfolio co Istesso phase 2a trials, R&D collab
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and the date, indicating it is a regulatory announcement disseminated via the London Stock Exchange's Regulatory News Service (RNS). The content details an operational update regarding a subsidiary's drug trial progression (Phase 2a commencement) and an expansion of a collaboration agreement. This type of material—a specific, timely corporate update that is not a full financial report (like 10-K or IR), a management change (MANG), or a dividend notice (DIV)—is typically classified as a general regulatory filing or announcement. Since 'RNS' is explicitly mentioned as the source/format, and it fits the description of a general regulatory announcement that doesn't fit other specific categories, the most appropriate code is RNS.
2017-08-22 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.